<DOC>
	<DOCNO>NCT02680418</DOCNO>
	<brief_summary>To determine pharmacokinetics single multiple dos FDL169 healthy female subject .</brief_summary>
	<brief_title>Pharmacokinetics FDL169 Healthy Female Subjects</brief_title>
	<detailed_description>This two-part study . Part 1 : Part 1 study single-dose , dose-escalation , study ass safety , tolerability PK profile follow oral administration FDL169 healthy female volunteer feed state . Up five dos assess . Part 2 : Part 2 study multiple-dose study ass safety , tolerability PK profile follow oral administration FDL169 healthy female volunteer feed state .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Healthy female subject age 18 55 year inclusive ethnic origin body mass index ( BMI ) &gt; 19 &lt; 30 kg/m2 . Body Mass Index = Body weight ( kg ) / [ Height ( ) ] 2 . Subjects must willing use effective method contraception first dose investigational medicinal product ( IMP ) 3 month last dose IMP ( unless nonchild bear potential ) . 1 . Participation New Chemical Entity clinical study within previous 4 month market drug clinical study within previous 3 month . 2 . Subjects renal clinically significant cardiac , renal hepatic disease Screening . 3 . Subjects history presence clinically significant cardiovascular , pulmonary , renal , hepatic , haematologic , gastrointestinal ( exception Gilbert 's syndrome asymptomatic gallstone ) , endocrine immunologic disease Screening . 4 . Have abnormal twelvelead ECG ECG abnormality consider clinically significant opinion Investigator ECG single QTcB &gt; 450 mSec . 5 . Subjects positive urinary drug abuse screen positive alcohol screen Screening Day 1 . 6 . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit . 7 . Subject history HIV positive human immunodeficiency virus , hepatitis B hepatitis C result . 8 . Donation 500 mL blood within previous 3 month . 9 . Use prescription nonprescription drug , include vitamin , herbal dietary supplement within 14 day 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator FDL Medical Monitor medication interfere study procedure compromise subject safety . 10 . Smoking use tobacco product substitute equivalent &gt; 15 cigarettes/day . 11 . Any subject pregnant nursing .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>